[Development of intelligent DDS technologies].
Recently, biologically active therapeutic peptides have been artificially synthesized by genetic engineering techniques. These peptides are easily degraded under physiological conditions and also encounter absorption problems due to their high molecular weight. Hence, they cannot be utilized effectively in conventional dosage forms. For such active agents, new types of DDS must be developed to deliver the drug effectively to the target site (targeted, site-specific delivery) and release drug when drug is required (temporal control) in addition to conventional rate-controlling systems. To realize such drug release systems, it is important to construct a system where drug itself senses an environmental stimuli and responds to appropriately control drug release. Such systems are described as "intelligent DDS", as distinguished from conventional DDS.